CyberKnife Stereotactic Radiotherapy as Monotherapy for Low- to Intermediate-Stage Prostate Cancer: Early Experience, Feasibility, and Tolerance

Aluwini, S.; Rooij, Peter van; Hoogeman, M.S.; Bangma, Chris H.; Kirkels, Wim J.; Incrocci, Luca; Kolkman-Deurloo, I.K.K.

doi:10.1089/end.2009.0438

Cited by 50 publications

(50 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Stereotactic body radiotherapy (SBRT) has recently emerged as an alternative technique to deliver hypofractionated radiotherapy to the prostate, comparable in many respects to HDR brachytherapy, but with a noninvasive approach [8][9][10][11][12][13][14]. The concept is not entirely novel.…”

Section: Introductionmentioning

confidence: 99%

Stereotactic body radiotherapy for low-risk prostate cancer: Five-year outcomes.

Freeman

King

2011

JCO

View full text Add to dashboard Cite

Purpose: Hypofractionated, stereotactic body radiotherapy (SBRT) is an emerging treatment approach for prostate cancer. We present the outcomes for low-risk prostate cancer patients with a median follow-up of 5 years after SBRT. Results: At a median follow-up of 5 years, the biochemical progression-free survival was 93% (95% CI = 84.7% to 100%). Acute side effects resolved within 1-3 months of treatment completion. There were no grade 4 toxicities. No late grade 3 rectal toxicity occurred, and only one late grade 3 genitourinary toxicity occurred following repeated urologic instrumentation. Conclusion: Five-year results of SBRT for localized prostate cancer demonstrate the efficacy and safety of shorter courses of high dose per fraction radiation delivered with SBRT technique. Ongoing clinical trials are underway to further explore this treatment approach. Method and

show abstract

Section: Introductionmentioning

confidence: 99%

Stereotactic body radiotherapy for low-risk prostate cancer: Five-year outcomes.

Freeman

King

2011

JCO

View full text Add to dashboard Cite

show abstract

“…Consequently, researchers have used brachytherapy as a boost within the prostate following EBRT or IMRT delivery of [45][46][47][48][49][50] Gy to the prostate and surrounding tissues. As noted earlier, HDR brachytherapy as a boost to EBRT or IMRT can achieve 5-8 year freedom from biochemical failure rates of 85-90% and 68-73% for intermediate-and high-risk disease, respectively [23,57].…”

Section: Sbrt As a Boost For Higher Risk Diseasementioning

confidence: 99%

Stereotactic body radiotherapy for prostate cancer: ready for prime time?

Katz

2012

J Radiat Oncol

View full text Add to dashboard Cite

Stereotactic body radiotherapy (SBRT) delivers a few high doses of radiation to a target in the body with extreme accuracy and conformality. Prostate cancer's great sensitivity to dose per fraction allows SBRT's hypofractionated delivery the opportunity to increase the biological equivalent dose delivered to the prostate while relatively decreasing the dose to the normal bladder and rectal tissues. In recent years, clinical outcomes supporting the safety and increasingly longer-term efficacy of SBRT have been published. This review examines the basis of hypofractionation, current SBRT delivery mechanisms, and the growing body of clinical outcomes of SBRT for prostate cancer. In addition, given the increased interest in SBRT for prostate cancer, clinical issues in the treatment of prostate cancer with SBRT and a look into the future of SBRT for prostate cancer are examined.

show abstract

“…At a median follow-up of 18 months 87% percent (198/228) of patients maintained erectile (Friedland et al 2009). The results of other published but small single-institution trials are summarized in Table 11 (Katz et al 2010;Wiegner and King 2010;Aluwini et al 2010;Friedland et al 2009;King et al 2009;Morgia and De Renzis 2009;Fuller et al 2008;Madsen et al 2007). Several randomised trials have indicated that by increasing the dose to the prostate better biochemical control is obtained.…”

Section: Sbrt For Prostate Cancermentioning

confidence: 99%

“…As is the case for conventionally fractionated external beam radiotherapy for prostate cancer there is no consensus on rectal preparation and bladder filling in stereotactic radiotherapy. Some authors advocate the use of low fiber diets and pre-treatment laxatives (Aluwini et al 2010) or anti flatulent medication after each meal (Madsen et al 2003). However, so far none of these approaches was proven to be superior.…”

Section: Sbrt For Prostate Cancermentioning

confidence: 99%

Stereotactic Body Radiotherapy

et al. 2011

View full text Add to dashboard Cite

CyberKnife Stereotactic Radiotherapy as Monotherapy for Low- to Intermediate-Stage Prostate Cancer: Early Experience, Feasibility, and Tolerance

Abstract: This regimen of stereotactic CK monotherapy for low- to intermediate-risk prostate cancer with excellent dose coverage of the prostate was well tolerated. Data collection is ongoing for further assessment of toxicity and PSA response.

Cited by 50 publications

References 26 publications

Stereotactic body radiotherapy for low-risk prostate cancer: Five-year outcomes.

Stereotactic body radiotherapy for low-risk prostate cancer: Five-year outcomes.

Stereotactic body radiotherapy for prostate cancer: ready for prime time?

Stereotactic Body Radiotherapy

Contact Info

Product

Resources

About